Adverse Event reporting information can be found in footer
Important Update
Product Name Change from Glypressin® to Terlipressin Acetate
As of the 1st May 2024, Ferring will be removing the brand name GLYPRESSIN® (terlipressin acetate) from our 1mg powder and solvent for solution for injection vials, and our 0.12mg/ml solution for injection ampoules.
The product will be sold under its generic name, terlipressin acetate, from May 2024.
Job Code: UK-GN-2400012 – Date of Preparation: April 2024
Ferring has a strong heritage of educational support, sponsorship and clinical research within Inflammatory Bowel Disease (IBD).
Here you can find information about our products, along with prescribing information and dosing. You can also find out about educational events that we support and learning resources for you to download.
Job Code: UK-GAS-2200154 - Date of preparation: November 2022
Our use of cookies
We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.
Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.
Necessary cookies
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
Analytics cookies
We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.
